Sylentis Concludes Phase Ia Study of Glaucoma Drug | GenomeWeb

Sylentis announced this week that it has completed a phase Ia study of its siRNA-based glaucoma drug SYL040012.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Gene Silencing News first reported in April that the trial had been concluded and that SYL040012 proved to be both safe and well tolerated (GSN 4/1/2010).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.